Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
P/E ratio for Scilex Holding Company (SCLX)
P/E ratio as of 2023: -2.32
According to Scilex Holding Company's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.32. At the end of 2022 the company had a P/E ratio of -22.92.
P/E ratio history for Scilex Holding Company from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.32 |
| 2022 | -22.92 |
| 2021 | -15.09 |
| 2020 | -29.25 |
| 2019 | -7.78 |